JP MORGAN/CALL/ELI LILLY & CO/640/0.1/17.01.25 | Delayed Börse Stuttgart 09:18:51 21/06/2024 BST | ||
| 25.58 EUR | -1.73% |
|
| Current month | +30.08% | ||
| 1 month | +61.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 25.58 | -1.73% |
| 20/06/24 | 26.03 | +0.04% |
| 19/06/24 | 26.02 | +1.17% |
| 18/06/24 | 25.72 | +2.23% |
| 17/06/24 | 25.16 | -1.80% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 09:18 am
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JL539C |
| ISIN | DE000JL539C0 |
| Date issued | 29/06/2023 |
| Strike | 640 $ |
| Maturity | 17/01/2025 (211 Days) |
| Parity | 10 : 1 |
| Emission price | 1.82 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.03 € |
|---|---|
| Lowest since issue | 1.46 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 1.384 |
| Difference Strike | -246 $ |
| Difference Strike % | -38.44% |
| Intrinsic value | 23.01 |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
886
USD
Average target price
855.4
USD
Spread / Average Target
-3.45%
- Stock Market
- Warrants
- Warrant
